Table 3. Associations of successful composite immunologic response with clinical and laboratory variables.
| Variable | Univariate p-value | Forward step model | ||
|---|---|---|---|---|
| Coefficient estimate (95% CI) | p-value | Unit Odds (95% CI) | ||
| Burn diagnosis | 0.004 | 1.09 (0.22–1.98) | 0.015 | 8.98 (1.54–52.3) |
| Days from admission to PPSV23 administration | 0.01 | -0.4 (-0.76–-0.04) | 0.022 | 0.67 (0.47–0.96) |
| Age | 0.02 | Age, CRP, WBC, Hospital non-survivor, and APACHE II score did not meet criteria to be significantly additive in association with the outcome of successful composite immunologic response by forward step method (p >0.2 for each). | ||
| CRP | 0.1 | |||
| Highest WBC within 24 hours of admission | 0.12 | |||
| Hospital non-survivor | 0.13 | |||
| APACHE II score | 0.15 | |||
PPSV23, 23-valent pneumococcal polysaccharide vaccine; CRP, C-reactive protein; WBC, white blood cell count; APACHE II, Acute Physiology and Chronic Health Evaluation II